Ohcanbohtosat - Ensar Halilovic

Aiddostahte ozu
  1. 1
    Centrosomal Anchoring of Protein Kinase C βII by Pericentrin Controls Microtubule Organization, Spindle Function, and Cytokinesis

    Centrosomal Anchoring of Protein Kinase C βII by Pericentrin Controls Microtubule Organization, Spindle Function, and Cytokinesis Dahkki Dan Chen, Aruna Purohit, Ensar Halilovic, Stephen Doxsey, Alexandra C. Newton

    Almmustuhtton 2004
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  2. 2
    PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling

    PIK3CA Mutation Uncouples Tumor Growth and Cyclin D1 Regulation from MEK/ERK and Mutant KRAS Signaling Dahkki Ensar Halilovic, Qing‐Bai She, Qing Ye, Raymond Pagliarini, William R. Sellers, David B. Solit, Neal Rosen

    Almmustuhtton 2010
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  3. 3
    4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors

    4E-BP1 Is a Key Effector of the Oncogenic Activation of the AKT and ERK Signaling Pathways that Integrates Their Function in Tumors Dahkki Qing‐Bai She, Ensar Halilovic, Qing Ye, Zhen Wei, Senji Shirasawa, Takehiko Sasazuki, David B. Solit, Neal Rosen

    Almmustuhtton 2010
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  4. 4
    A novel human protein of the maternal centriole is required for the final stages of cytokinesis and entry into S phase

    A novel human protein of the maternal centriole is required for the final stages of cytokinesis and entry into S phase Dahkki Adam Gromley, Agata Jurczyk, James Sillibourne, Ensar Halilovic, Mette M. Mogensen, Irina Groisman, M. B.V. von Blomberg, Stephen Doxsey

    Almmustuhtton 2003
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  5. 5
    The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

    The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner Dahkki Eric W. Joseph, Christine A. Pratilas, Poulikos I. Poulikakos, Madhavi Tadi, Weiqing Wang, Barry S. Taylor, Ensar Halilovic, Yogindra Persaud, Feng Xing, Agnès Viale, James Tsai, Paul B. Chapman, Gideon Bollag, David B. Solit, Neal Rosen

    Almmustuhtton 2010
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  6. 6
    Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models

    Combined ALK and MDM2 inhibition increases antitumor activity and overcomes resistance in human ALK mutant neuroblastoma cell lines and xenograft models Dahkki Hui Qin Wang, Ensar Halilovic, Xiaoyan Li, Jinsheng Liang, Yichen Cao, Daniel P. Rakiec, David A. Ruddy, Sébastien Jeay, Jens Wuerthner, Noelito Timple, Shailaja Kasibhatla, Nanxin Li, Juliet Williams, William R. Sellers, Alan Huang, Fang Li

    Almmustuhtton 2017
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  7. 7
    MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer

    MDM2 inhibition in combination with endocrine therapy and CDK4/6 inhibition for the treatment of ER-positive breast cancer Dahkki Neil Portman, Heloisa Milioli, Sarah Alexandrou, Rhiannon Coulson, Aliza Yong, Kristine J. Fernandez, Kee Ming Chia, Ensar Halilovic, Davendra Segara, Andrew Parker, Sue Haupt, Ygal Haupt, Wayne D. Tilley, Alexander Swarbrick, C. Elizabeth Caldon, Elgene Lim

    Almmustuhtton 2020
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  8. 8
    Genetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer

    Genetic Predictors of MEK Dependence in Non–Small Cell Lung Cancer Dahkki Christine A. Pratilas, Aphrothiti J. Hanrahan, Ensar Halilovic, Yogindra Persaud, Junichi Soh, Dhananjay Chitale, Hisayuki Shigematsu, Hiromasa Yamamoto, Ayana Sawai, Manickam Janakiraman, Barry S. Taylor, William Pao, Shinichi Toyooka, Marc Ladanyi, Adi F. Gazdar, Neal Rosen, David B. Solit

    Almmustuhtton 2008
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  9. 9
    Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma

    Dual inhibition of protein kinase C and p53-MDM2 or PKC and mTORC1 are novel efficient therapeutic approaches for uveal melanoma Dahkki Guillaume Carita, Estelle Frisch-Dit-Leitz, Ahmed Dahmani, Chloé Raymondie, Nathalie Cassoux, Sophie Piperno‐Neumann, Fariba Némati, Cécile Laurent, Leanne de Koning, Ensar Halilovic, Sébastien Jeay, Andrew A. Wylie, W. Marston Linehan, Sergio Román-Román, Marie Schoumacher, Didier Decaudin

    Almmustuhtton 2016
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  10. 10
    Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas

    Relief of Profound Feedback Inhibition of Mitogenic Signaling by RAF Inhibitors Attenuates Their Activity in BRAFV600E Melanomas Dahkki Piro Lito, Christine A. Pratilas, Eric W. Joseph, Madhavi Tadi, Ensar Halilovic, Matthew Zubrowski, Alan Huang, Wai Lin Wong, Margaret K. Callahan, Taha Merghoub, Jedd D. Wolchok, Elisa de Stanchina, Sarat Chandarlapaty, Poulikos I. Poulikakos, James A. Fagin, Neal Rosen

    Almmustuhtton 2012
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  11. 11
    Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study

    Co-Targeting of MDM2 and CDK4/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Conce... Dahkki Albiruni R. Abdul Razak, Sebastian Bauer, Cristina Suárez, Chia‐Chi Lin, Richard Quek, Marie Luise Hütter‐Krönke, Ricardo Cubedo, Stéphane Ferretti, Nelson Guerreiro, Astrid Jullion, Elena J. Orlando, Giorgia Clementi, Janna Dejmek, Ensar Halilovic, Claire Fabre, Jean‐Yves Blay, Antoîne Italiano

    Almmustuhtton 2021
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  12. 12
    MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21

    MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21 Dahkki Anna E. Vilgelm, Nabil Saleh, Rebecca L. Shattuck-Brandt, Kelsie Riemenschneider, Lauren Slesur, Sheau‐Chiann Chen, Christopher Andrew Johnson, Jinming Yang, Ashlyn Blevins, Chi Yan, Douglas B. Johnson, Rami N. Al‐Rohil, Ensar Halilovic, Rondi M. Kauffmann, Mark C. Kelley, Gregory D. Ayers, Ann Richmond

    Almmustuhtton 2019
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  13. 13
    Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment

    Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment Dahkki Hui Qin Wang, Iain J. Mulford, Fiona A. Sharp, Jinsheng Liang, Sema Kurtuluş, Gina M. Trabucco, David S. Quinn, Tyler A. Longmire, Nidhi Patel, Roshani Patil, Matthew D. Shirley, Yan Chen, Hao Wang, David A. Ruddy, Claire Fabre, Juliet Williams, Peter S. Hammerman, Jennifer Mataraza, Barbara Platzer, Ensar Halilovic

    Almmustuhtton 2021
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  14. 14
    Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097

    Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097 Dahkki Ellen Weisberg, Ensar Halilovic, Vesselina G. Cooke, Atsushi Nonami, Tao Ren, Takaomi Sanda, Irene Simkin, Jing Yuan, Brandon Antonakos, Louise Barys, Moriko Ito, Richard M. Stone, Ilene Galinsky, Kristen Cowens, Erik A. Nelson, Martin Sattler, Sébastien Jeay, Jens Wuerthner, Sean M. McDonough, Marion Wiesmann, James D. Griffin

    Almmustuhtton 2015
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  15. 15
    A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097

    A distinct p53 target gene set predicts for response to the selective p53–HDM2 inhibitor NVP-CGM097 Dahkki Sébastien Jeay, Swann Gaulis, Stéphane Ferretti, Hans Bitter, Moriko Ito, Therese‐Marie Stachyra, Masato Murakami, Stephan Ruetz, Daniel Guthy, Caroline Rynn, Michael Rugaard Jensen, Marion Wiesmann, Joerg Kallen, Pascal Furet, F. Gessier, Philipp Holzer, Keiichi Masuya, Jens Würthner, Ensar Halilovic, Francesco Hofmann, William R. Sellers, Diana Graus Porta

    Almmustuhtton 2015
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  16. 16
    Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma

    Preclinical evaluation of the simultaneous inhibition of MCL-1 and BCL-2 with the combination of S63845 and venetoclax in multiple myeloma Dahkki Esperanza M. Algarín, Andrea Díaz-Tejedor, Pedro Mogollón, Susana Hernández-García, Luís A. Corchete, Laura San‐Segundo, Montserrat Martín-Sánchez, Lorena González-Méndez, Marie Schoumacher, Sébastien Banquet, Laurence Kraus‐Berthier, Ioana Kloos, Alix Derréal, Ensar Halilovic, Heiko Maacke, Norma C. Gutiérrez, María‐Victoria Mateos, Teresa Paíno, Mercedes Garayoa, Enrique M. Ocio

    Almmustuhtton 2019
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  17. 17
    Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer

    Genomic and Biological Characterization of Exon 4 KRAS Mutations in Human Cancer Dahkki Manickam Janakiraman, Efsevia Vakiani, Zhaoshi Zeng, Christine A. Pratilas, Barry S. Taylor, Dhananjay Chitale, Ensar Halilovic, Manda Wilson, Kety Huberman, Julio Cezar Ricarte Filho, Yogindra Persaud, Douglas A. Levine, James A. Fagin, Suresh C. Jhanwar, John M. Mariadason, Alex E. Lash, Marc Ladanyi, Leonard B. Saltz, Adriana Heguy, Philip B. Paty, David B. Solit

    Almmustuhtton 2010
    Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  18. 18
    Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia

    Reduced Mitochondrial Apoptotic Priming Drives Resistance to BH3 Mimetics in Acute Myeloid Leukemia Dahkki Shruti Bhatt, Marissa S. Pioso, Elyse A. Olesinski, Binyam Yilma, Jeremy Ryan, Thelma Mashaka, Leutz Buon, Sophia Adamia, Haoling Zhu, Yanan Kuang, Abhishek R. Mogili, Abner Louissaint, Stephan Bohl, Annette S. Kim, Anita K. Mehta, Sneha Sanghavi, Youzhen Wang, Erick J. Morris, Ensar Halilovic, Cloud P. Paweletz, David M. Weinstock, Jacqueline S. Garcia, Anthony Letai

    Almmustuhtton 2020
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  19. 19
    Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type <i>TP53</i> Solid Tumors and Acute Leukemia

    Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type <i>TP53</i> Solid Tumors and Acute Leukemia Dahkki Eytan M. Stein, Daniel J. DeAngelo, Jörg Chromik, Manik Chatterjee, Sebastian Bauer, Chia‐Chi Lin, Cristina Suárez, Filip De Vos, Neeltje Steeghs, Philippe A. Cassier, David Tai, Jean‐Jacques Kiladjian, Noboru Yamamoto, Rogier Mous, Jordi Esteve, Hironobu Minami, Stéphane Ferretti, Nelson Guerreiro, Christophe Meille, Rajkumar Radhakrishnan, Bernard Pereira, Luisa Mariconti, Ensar Halilovic, Claire Fabre, Cecilia Carpio

    Almmustuhtton 2021
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:
  20. 20
    Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201

    Dose and Schedule Determine Distinct Molecular Mechanisms Underlying the Efficacy of the p53–MDM2 Inhibitor HDM201 Dahkki Sébastien Jeay, Stéphane Ferretti, Philipp Holzer, Jeanette Fuchs, Emilie A. Chapeau, Markus Wartmann, Dario Sterker, Vincent Romanet, Masato Murakami, Gráinne Kerr, Eric Y. Durand, Swann Gaulis, Marta Cortés-Cros, Stephan Ruetz, Therese‐Marie Stachyra, Joerg Kallen, Pascal Furet, Jens Würthner, Nelson Guerreiro, Ensar Halilovic, Astrid Jullion, Audrey Kauffmann, Emil Kuriakose, Marion Wiesmann, Michael Rugaard Jensen, Francesco Hofmann, William R. Sellers

    Almmustuhtton 2018
    Viečča ollesdeavstta Viečča ollesdeavstta
    Artigo
    Lasit oiddohiidda
    Furkejuvvon:

Ohcanreaiddut: